Introduction {#s01}
============

Hematopoietic stem cells (HSCs) produce differentiated cells to replenish the blood system through the lifetime. The quiescence of HSCs is a defining characteristic for their maintenance during homeostasis and regeneration post-injury ([@bib35]). Several bone marrow (BM) niche cells, such as mesenchymal stem cells (MSCs), nonmyelinating Schwann cells, and megakaryocytes (MKs) are known to maintain HSC quiescence ([@bib41]; [@bib14]; [@bib4]; [@bib42]; [@bib9]). Although the quiescent signals from MSCs need further characterization, it is clear that MKs and nonmyelinating Schwann cells regulate HSC quiescence by coordinating TGF-β signaling ([@bib41]; [@bib42]). TGF-β is a key signal for HSC quiescence regulation ([@bib40]; [@bib2]); however, it is unclear how this niche signal regulates HSC quiescence through its intrinsic mechanisms.

SHP-1 is an SH2 domain--containing protein tyrosine phosphatase that controls the intracellular phosphotyrosine levels ([@bib37]; [@bib17]). SHP-1 is expressed in all hematopoietic cells and attenuates receptor tyrosine kinase pathways initiated by growth factors and cytokines ([@bib21]). SHP-1 inhibits cell growth and suppresses their oncogenic potentials in lymphocytes ([@bib32]; [@bib34]; [@bib5]). Loss of SHP-1 expression in B cells or dendritic cells results in elevated B-1a or Th1 cell differentiation and induces autoimmunity ([@bib22]; [@bib11]). Loss of SHP-1 expression in tumor-specific T cells, or natural killer cells, promotes their immune responsiveness and antitumor function ([@bib30]; [@bib34]). Our data suggest that SHP-1 might be involved in hematopoiesis and leukemogenesis, by interacting with immunoreceptor tyrosine-based inhibition motif (ITIM)--bearing receptors such as LAIR1 and LILRB2 ([@bib45]; [@bib12], [@bib13]). However, whether SHP-1 directly contributes to HSC regulation is unknown. In this work, we found that SHP-1 is critical for TGF-β--mediated HSC quiescence control.

Results and discussion {#s02}
======================

Loss of SHP-1 results in HSC activation and subsequent exhaustion {#s03}
-----------------------------------------------------------------

To obtain an inducible loss-of-function model for SHP-1 in HSCs, we crossed *Shp-1^fl/fl^* mice ([@bib25]) with transgenic mice expressing the tamoxifen-inducible Cre recombinase under the control of the stem cell leukemia (Scl) enhancer, which enabled knockout of floxed genes in HSCs and hematopoietic progenitors, upon tamoxifen treatment ([@bib6]). The resultant *Scl-CreER^+^; Shp-1^fl/fl^* (*Shp-1^Δ/Δ^*) mice and the control mice *Scl-CreER^--^; Shp-1^fl/fl^* (*Shp-1^+/+^*) were treated with tamoxifen to initiate *Shp-1* knockout in HSCs ([Fig. 1 A](#fig1){ref-type="fig"}). The control mice had a normal lifespan. However, *Shp-1^Δ/Δ^* mice began to die ∼40 d after tamoxifen treatment ([Fig. 1 B](#fig1){ref-type="fig"}). Furthermore, we found that the total number of BM cells in *Shp-1^Δ/Δ^* mice was increased ∼37% at 2 wk, but reduced ∼45% at 4 wk and further reduced ∼60% at ∼7 wk (at moribund), after tamoxifen treatment ([Fig. 1 C](#fig1){ref-type="fig"}). The dynamic change of BM cell numbers indicated that there was a transient activation with subsequent exhaustion of hematopoiesis as a result of SHP-1 knockout in HSCs.

![**Loss of *Shp-1* results in HSC activation and subsequent exhaustion. (A)** Schema for tamoxifen treatment and sample analysis time points. TMX, tamoxifen; W, week. **(B)** Survival curves of *Scl-CreER^--^;Shp-1^fl/fl^* (*Shp-1^+/+^*) and *Scl-CreER^+^;Shp-1^fl/fl^* (*Shp-1^Δ/Δ^*) mice treated with tamoxifen (*n* = 23 mice; P \< 0.0001, log-rank test). **(C)** Total BM cell numbers in *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice at indicated time points after tamoxifen treatment (*n* = 3 mice). TNC, total nucleated cells. **(D)** Comparison of LT-HSC, ST-HSC, and MPP numbers in *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice at three time points after tamoxifen treatment (*n* = 10 mice). **(E)** Flow cytometry analysis of cell cycle stage of BM cells from *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice harvested 4 wk after tamoxifen treatment. Left panel shows the representative flow cytometry plots. Right panel plots percentages of *Shp-1^+/+^* and *Shp-1^Δ/Δ^* cells in each stage of the cell cycle (*n* = 3 mice). **(F)** Flow cytometry analysis of early (detected as Annexin V^+^/7-AAD^−^ staining) and late (detected as Annexin V^+^/7-AAD^+^ staining) apoptotic HSCs from BM of tamoxifen-treated *Shp-1* KO mice (*n* = 3 mice). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. ns, not significant. Error bars show mean ± SEM.](JEM_20171477_Fig1){#fig1}

To explore the effect of *Shp-1* knockout in HSCs, we investigated the phenotypic HSCs and hematopoietic progenitors in the BM from the *Shp-1^Δ/Δ^* and *Shp-1^+/+^* control mice. We found that long-term HSCs (LT-HSCs), identified as Lin^--^Sca-1^+^Kit^+^CD34^--^Flk2^--^ cells, were increased ∼4.5-fold at 2 wk after tamoxifen treatment in *Shp-1^Δ/Δ^* mice compared with their control counterparts. Similarly, short-term HSCs (ST-HSCs; Lin^--^Sca-1^+^Kit^+^CD34^+^Flk2^--^) and hematopoietic multipotent progenitors (MPPs; Lin^--^Sca-1^+^Kit^+^CD34^+^Flk2^+^) were increased ∼3.6-fold and ∼4.1-fold, respectively, in *Shp-1^Δ/Δ^* mice compared with control *Shp-1^+/+^* mice. Furthermore, LT-HSC, ST-HSC, and MPPs were also increased ∼5.2-fold, 2.9-fold, and 3.4-fold, respectively, in *Shp-1^Δ/Δ^* mice compared with controls at 4 wk after tamoxifen treatment. However, LT-HSCs were decreased ∼35%, and ST-HSCs and MPPs were decreased ∼63.8% and ∼51.6%, respectively, in *Shp-1^Δ/Δ^* mice compared with controls when *Shp-1^Δ/Δ^* mice were moribund ([Fig. 1 D](#fig1){ref-type="fig"}). The data suggest that HSCs were activated for proliferation at the early stage when *Shp-1* was knocked out; however, this activation led to HSC exhaustion, which is responsible for the total BM cell reduction and moribund phenotype.

To identify whether *Shp-1* deletion truly triggered HSC activation, we analyzed the cell cycle profile of HSCs at 4 wk after tamoxifen treatment. We found that the percentage of HSCs in G0 phase was reduced by 55.4%, whereas the G1 phase showed a ∼1.8-fold increase in *Shp-1^Δ/Δ^* mice compared with the control, which indicated the greatly decreased quiescence of HSCs after SHP-1 knockout ([Fig. 1 E](#fig1){ref-type="fig"}). We did not observe a significant difference in apoptosis in HSCs between *Shp-1^Δ/Δ^* and *Shp-1^+/+^* mice ([Fig. 1 F](#fig1){ref-type="fig"}). The absence of *Shp-1* causes activation of differentiated hematopoietic cells, which may compromise HSC functions. We further analyzed *Shp-1^Δ/Δ^* mice at 1 wk after tamoxifen treatment, when no activation of mature hematopoietic cells was observed, and found that the HSC quiescence was greatly decreased (40% reduction in G0) before HSC number increased (Fig. S1). Additionally, MKs have functional ITIM receptors that activate SHP-1, and *Shp-1*--null MKs show abnormal development and function ([@bib19]). Then, we further used platelet factor 4-cre (*Pf4-cre*) to specifically delete *Shp-1* in MKs by generating the *Pf4-cre; Shp-1^fl/fl^* line ([@bib33]). We found that deletion of *Shp-1* in MKs did not influence HSCs either in number or their cell cycle (Fig. S2). Overall, our data suggested that SHP-1 prevents exhaustion by maintaining HSC quiescence.

Loss of *SHP-1* reduced HSC long-term self-renewal {#s04}
--------------------------------------------------

To evaluate the HSC functional change after *Shp-1* knockout, we performed competitive transplantation experiments. As shown in [Fig. 2 A](#fig2){ref-type="fig"}, we transplanted 500 LT-HSCs from tamoxifen-treated *Shp-1^Δ/Δ^* or *Shp-1^+/+^* control animals with competitor cells into lethally irradiated recipients. We found that HSCs from *Shp-1^Δ^*^/^*^Δ^* mice showed a significantly higher level of donor cell reconstitution (∼1.4-fold at 16 wk after transplantation, P = 0.0074) than their counterparts. We did not observe any biased lineage reconstitution ([Fig. 2 A](#fig2){ref-type="fig"}). To further explore whether loss of *Shp-1* affects HSC long-term self-renewal, we performed a secondary transplantation. Interestingly, we found that *Shp-1*--null HSCs gradually lost their ability for hematopoietic reconstitution. The donor cell reconstitution of *Shp-1*--null HSCs was significantly reduced at 24 wk after secondary transplantation (74.2% reduction, P = 0.0022) compared with *Shp-1^+/+^* HSCs. We also observed that *Shp-1*--null HSCs generated more B lymphocytes than control HSCs (46.2% vs. 16.8%), but less myeloid cells (42.2% vs. 76.1%; [Fig. 2 B](#fig2){ref-type="fig"}). Overall, this indicated that the loss of *Shp-1* in HSCs caused increased activation and proliferation but impaired long-term self-renewal.

![**Loss of *Shp-1* reduced HSC long-term self-renewal. (A and B)** Competitive reconstitution analysis using 500 HSCs from tamoxifen-treated *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice. Peripheral blood analysis for total engrafted donor cells at the indicated number of weeks after primary transplantation (1°; A) and secondary transplantation (2°; B) and the percentage of donor-derived B, T, and myeloid lineage cells at 16 wk of primary transplantation (right panel of A) and at 24 wk of secondary transplantation (right panel of B; *n* = 5 mice per group). **(C and D)** Limiting dilution assays comparing the frequencies of HSC in *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice. BM cells were collected 4 wk after tamoxifen treatment. The repopulation percentages were detected 20 wk after transplant of *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice (C) and plot of competitive repopulating units (CRUs) calculated using ELDA (P = 0.009; D). *n* = 5 mice per group. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Error bars show mean ± SEM.](JEM_20171477_Fig2){#fig2}

To quantify the number of functional HSCs in *Shp-1^Δ^*^/^*^Δ^* mice, we performed a competitive repopulation unit (CRU) assay. 50,000, 20,000, and 8,000 BM cells from *Shp-1^Δ^*^/^*^Δ^* mice or *Shp-1^+/+^* controls were transplanted into irradiated recipients with 200,000 competitor cells. The percentage of donor cell reconstitution was measured at 40 wk after transplantation ([Fig. 2 C](#fig2){ref-type="fig"}) to quantify the number of functional HSCs per mice. We found that the frequency of HSCs in *Shp-1^Δ^*^/^*^Δ^* mice was 1 per 64,623, which was ∼78% less than the frequency (1 per 14,203) in *Shp-1^+/+^* control mice (P = 0.009; [Fig. 2 D](#fig2){ref-type="fig"}). Overall, our data demonstrated that the loss of SHP-1 induced transient HSC activation and proliferation, but reduced functional long-term self-renewal of HSCs.

SHP-1 interacts with TGF-β receptor 1 (TβRI) and coordinates TGF-β signaling. {#s05}
-----------------------------------------------------------------------------

To understand the mechanism of SHP-1 in regulating HSC quiescence, we performed immunostaining to investigate how SHP-1--activated HSCs are maintained in the BM niche. We found that ∼44% of HSCs are pSHP-1^+^ and interestingly, pSHP-1^+^ HSCs were significantly associated with MKs compared with pSHP-1^--^ HSCs (P = 0.023; [Fig. 3, A--C](#fig3){ref-type="fig"} and Fig. S3). This finding is in line with our study that MKs maintain HSC quiescence by TGF-β signaling ([@bib42]). Furthermore, we hypothesized that SHP-1 might regulate HSC quiescence by coordinating TGF-β signaling. Consistent with *Shp1* knockout the loss of TGF-β signaling resulted in transient HSC activation, but repressed long-term self-renewal potential. Our data showed that the knockout of TGF-β1 from MKs resulted in increased reconstitution of BM cells from *Pf4-cre^+^; TGF-β1^f/f^* compared with *Pf4-cre^--^; TGF-β1^f/f^* control mice (1.35-fold increase at 16 wk after transplantation, P = 0.028; [Fig. 3 D](#fig3){ref-type="fig"}, left). However, the reconstitution was decreased by 40% at 24 wk after secondary transplantation (P = 0.038; [Fig. 3 D](#fig3){ref-type="fig"}, right). We further found that TGF-β1 protein expression in BM was remarkably reduced (85.2% reduction) by ELISA in *Pf4-cre^+^; TGF-β1^f/f^* mice compared with control *Pf4-cre^--^; TGF-β1^f/f^* mice ([Fig. 3 E](#fig3){ref-type="fig"}). This indicates that MKs are the major source of TGF-β1 protein in BM. Because MKs produce TGF-β1 in latent form and Schwann cells are the major activator for latent TGF-β1 in BM ([@bib41]), we further analyzed the association of MKs with Schwann cells in BM and found that a considerable fraction of MKs (35.4%, \<10 µm) were associated with Schwann cells ([Fig. 3, F and G](#fig3){ref-type="fig"}). To test the significance of this association, we compared the actual MKs and simulations of randomly placed MKs in relation to Schwann cells ([Fig. 3 G](#fig3){ref-type="fig"}). The observed mean distance of MKs to Schwann cells (25.89 µm) was statistically different from the mean distance of randomly placed MKs to Schwann cells (75.85 µm) ([Fig. 3 H](#fig3){ref-type="fig"}). Our data show that the observed association of MKs with Schwann cells is statistically different from a random distribution (P = 2.7 × 10^−14^ by two-sample Kolmogorov-Smirnov \[KS\] test; [Fig. 3 G](#fig3){ref-type="fig"}). This suggests a niche surrounding MKs and Schwann cells in BM dedicated to HSC maintenance. To explore the spatial arrangement of HSCs in MK--Schwann cell niche, we measured the distances of actual and randomly placed HSCs to MKs (d~MK~) and to Schwann cells (d~SW~), respectively ([Fig. 3 I](#fig3){ref-type="fig"}). The actual HSCs were significantly closer to MK--Schwann cell clusters compared with randomly placed HSCs (P = 1.6 × 10^−20^ by two-dimensional KS test with two samples; [Fig. 3, I and J](#fig3){ref-type="fig"}). Overall, our data suggest that MKs and Schwann cells may synergistically form a unique niche to coordinate TGF-β signaling for HSC regulation in BM.

![**The spatial relationship of pSHP-1^+^ HSCs in BM niche. (A)** Representative image of a BM section from a C57BL/6J mouse showing pSHP-1^+^ HSCs were surrounded by MKs. The yellow arrowheads indicate HSCs. Gray, lineage cells; green, MKs; red, HSCs; blue, pSHP-1. Dashed box indicates area of focus. Bars, 25 µm. **(B)** Percentage of pSHP-1^+^ HSCs in BM. **(C)** Distance between pSHP-1^+^ HSCs and pSHP-1^--^ HSCs to MKs as indicated (*n* = 311 HSCs from four mice in four independent experiments). **(D)** Competitive reconstitution analysis of functional HSCs from *Pf4-cre^--^; TGF-β1^f/f^* or from *Pf4-cre^+^; TGF-β1^f/f^* mice. Plots of peripheral blood analysis for total engrafted donor cells at the indicated number of weeks after primary transplantation (1°) and secondary transplantation (2°; *n* = 10). **(E)** TGF-β1 protein levels as determined by ELISA in BM from *Pf4-cre; TGF-β1^f/f^* mice (cre−, *n* = 4 mice; cre+, *n* = 5 mice). The spatial relationship of MKs and Schwann cells. **(F)** Representative image of a BM section showing CD41^+^ MKs (green) and GFAP^+^ Schwann cells (red). Bar, 100 µm. **(G)** Distance between MKs and Schwann cells. The numbers on the x axis indicate intervals of 10 µm (−10 indicates the interval 0--10; −20 indicates 10--20, and so on). P = 2.7 × 10^−14^ by two-sample KS test. **(H)** Probability distributions of the mean distances between MKs and Schwann cells derived from simulations of randomly positioned MKs and actual Schwann on maps of BM. Mean distances observed in situ (red line) are shown in relation to the grand mean (mean of the means) ± 3 SD (3σ, blue and dotted black lines, respectively). Probability P (μ \< 25.89 µm) = 2.2 × 10^−16^. *n* = 365 MKs from three mice in three independent experiments. **(I)** The spatial relationship of HSCs (red), MKs (blue), and Schwann cells (green). d~MK~ and d~SW~ indicate the distance between the HSC to the closest MK and Schwann cell, respectively. The arrowheads indicate HSCs. Bars, 25 µm. **(J)** 2D probability distribution of the distances between HSCs to MKs (d~MK~) and Schwann cells (d~SW~) in the BM. Upper panel, HSC distribution in the BM (*n* = 95 HSCs, from three mice); lower panel, randomized HSC distribution models generated by computational simulations of random HSC localization (P = 1.57 × 10^−20^ by 2D KS test with two samples). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20171477_Fig3){#fig3}

The consistent phenotype between TGF-β1 knockout from niche cells and SHP-1 knockout from HSCs suggested that SHP-1 might be involved in TGF-β signaling regulation. To investigate this hypothesis, we first measured the level of pSMAD2 (downstream effectors of TGF-β signaling). We found that the level of pSMAD2 was remarkably reduced in BM cells from *Shp-1^Δ^*^/^*^Δ^* mice than from control *Shp-1^+/+^* mice ([Fig. 4 A](#fig4){ref-type="fig"}). Consistently, the frequency of pSMAD2^+^ HSCs from *Shp-1^Δ^*^/^*^Δ^* mice was reduced by 53.6% compared with HSCs from *Shp-1^+/+^* controls ([Fig. 4 B](#fig4){ref-type="fig"}). Loss of SHP-1 resulted in decreased expression of TGF-β activated kinase binding protein 1 (TAB1; 72.5% reduction) and increased expression of TGF-β inhibitor SMAD7 (2.57-fold increase) in HSCs, which indicated the dampened TGF-β signal activity in HSCs. Furthermore, SHP-1--null HSCs have low expression of P57 (75.6% reduction), which is a SMAD2/3 downstream factor and is critical for TGF-β--mediated cell cycle arrest in HSCs ([@bib26]; [@bib39], [@bib40]). SHP-1--null HSCs also have a low expression of Musashi-2 (Msi2; 75.6% reduction), which controls TGF-β signaling in HSCs ([Fig. 4 C](#fig4){ref-type="fig"}; [@bib23]). Overall, these data indicated that SHP-1--null HSCs had reduced TGF-β signaling, which may account for their loss of quiescence.

![**SHP-1 interacts with TβRI and coordinates TGF-β signaling. (A)** Immunoblotting for pSMAD2 protein in BM Lin^−^ cells. Actin was used as a loading control. 1 and 2 indicate two individual mice. **(B)** Representative image and frequency of pSMAD2 in HSCs from *Shp-1^+/+^* or *Shp-1^Δ/Δ^* mice (*n* = 112 HSCs from *Shp-1^+/+^* mice; *n* = 166 HSCs from *Shp-1^Δ/Δ^* mice from three mice). The arrowheads indicate HSCs. Bars, 25 µm. **(C)** RT-qPCR analysis of genes in HSCs from *Shp-1^+/+^* or *Shp-1^Δ/Δ^* mice. **(D)** ITIM motif in TβRI is highly conserved among different species. **(E)** Coexpression of Flag SHP-1 WT and vector, or HA-TβRI, or HA-TβRII in 293T cells. Cell lysate were precipitated with Flag beads; both input and precipitation were immune-blotted with Flag or His antibodies. **(F)** SHP-1 binds with TβRI endogenously in THP1 cells in bidirectional pull-down assay. **(G)** SHP-1 binds with TβRI by the ITIM motif. ITIM motif deleted TβRI or WT TβRI was used in the coimmunoprecipitation assay in 293 T cells. **(H)** Representative images of sorted LT-HSCs immunostained with SHP-1 (green) and TβRI (red). Bars, 10 µm. \*\*\*, P \< 0.001. Error bars show mean ± SEM.](JEM_20171477_Fig4){#fig4}

Motif analysis showed that TβRI had a very conserved ITIM motif ([Fig. 4 D](#fig4){ref-type="fig"}; [@bib29]). SHP-1 is known to interact with and activate the ITIM-containing receptors ([@bib16]; [@bib1]; [@bib27]). To test whether SHP-1 physically interacts with TβRI, we performed the immunoprecipitation assay. Interestingly, our results showed that SHP-1 specifically interacted with TβRI, but not with TβRII, which does not have an ITIM motif ([Fig. 4 E](#fig4){ref-type="fig"}). This interaction can also be confirmed at endogenous level ([Fig. 4 F](#fig4){ref-type="fig"}), which rules out the possibility of artificial interaction as a result of protein overexpression. To further investigate whether the ITIM domain is essential for the interaction between SHP-1 and TβRI, we generated a ΔTβRI mutant with the ITIM domain deleted. As hypothesized, ΔTβRI mutant failed to interact with SHP-1 ([Fig. 4 G](#fig4){ref-type="fig"}). We also found that a portion of SHP-1 was localized in close proximity to TβRI in HSCs ([Fig. 4 H](#fig4){ref-type="fig"}). Overall, our data demonstrated that SHP-1 interacted with TβRI via the ITIM motif of TβRI and indicated that SHP-1 might regulate HSC quiescence by coordinating TGF-β signal.

SHP-1 regulates HSC quiescence by cooperating TGF-β signal {#s06}
----------------------------------------------------------

Because TGF-β1 is known to suppress HSC proliferation in vitro ([@bib15]; [@bib40]), we further investigated whether SHP-1 can regulate this process. As expected, TGF-β1 treatment significantly suppressed HSC proliferation (56% reduction), colony forming capability (48% reduction in CFU activity), and the pSMAD2 level in HSCs from *Shp-1^+/+^* control mice. However, no significant difference was observed in HSCs from *Shp-1^Δ^*^/^*^Δ^* mice after TGF-β1 treatment ([Fig. 5 A](#fig5){ref-type="fig"}). This demonstrated that TGF-β cannot suppress HSC proliferation in *Shp-1* null HSCs and indicated that SHP-1 might be critical for TGF-β signaling in regulating HSC quiescence. Next, we analyzed the cell cycle profile of HSCs after TGF-β1 treatment. Consistently, we found that TGF-β1 treatment significantly increased G0 phase (1.7-fold, P = 0.008) and reduced G1 phase (31.7%, P = 0.0002) HSCs in control *SHP-1^+/+^* mice. However, no significant cell cycle difference was observed in HSCs from *Shp-1^Δ^*^/^*^Δ^* mice after TGF-β1 treatment ([Fig. 5 B](#fig5){ref-type="fig"}).

![**SHP-1 regulates HSC quiescence by cooperating TGF-β signaling. (A and B)** *Shp-1*--deficient HSPCs are resistant to the inhibitory effect of TGF-β1 in vitro. LSK cells isolated from *Shp-1*^+/+^ and *Shp-1*^Δ/Δ^ mice were treated with or without 5 ng/ml TGF-β1 in ex vivo expansion medium. 5 d later, the cells were used in CFU assay (A, right) or calculated for total numbers (A, left). pSMAD2 and SMAD protein were measured (A, bottom). These cells were also used for HSC cell cycle analysis (B). **(C--E)** Scheme for LY364947 injection to *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice after tamoxifen administration (C). Comparison of LT-HSC numbers (*n* = 5 mice; D) and cell cycle stage of HSCs (*n* = 5 mice; E) from *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice as indicated. **(F)** LSK cells from *Shp-1*^Δ/Δ^ mice were treated with or without TGF-β1 after overexpression of SHP-1 or SHP-1. Cells were quantified for cell number (upper panel) and protein expression as indicated (lower panel). **(G)** Schematic showing the role of SHP-1 in TGF-β--mediated HSC quiescence regulation. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. ns, not significant. Error bars show mean ± SEM.](JEM_20171477_Fig5){#fig5}

To further investigate whether SHP-1 is critical for TGF-β regulated HSC quiescence in vivo, we treated mice with a small molecule inhibitor of TGF-β signaling (LY364947; [Fig. 5 C](#fig5){ref-type="fig"}). We found that in vivo inhibiting TGF-β signaling in control *Shp-1^+/+^* mice significantly promoted HSC proliferation (P = 0.013), but not in *Shp-1^Δ^*^/^*^Δ^* mice ([Fig. 5 D](#fig5){ref-type="fig"}). Coordinately, LY364947-treated *Shp-1^+/+^* animals have prolonged cycling of LT-HSCs (30% reduction of G0, P = 0.0016; a 1.5-fold increase of G1, P = 0.027; and a 2.8-fold increase of S/G2/M, P = 0.0038). However, *Shp-1^Δ^*^/^*^Δ^* mice did not respond to LY364947 treatment ([Fig. 5 E](#fig5){ref-type="fig"}). Furthermore, we found that SHP-1, but not SHP-2, can rescue the proliferation inhibition response to TGF-β1 treatment (47% reduction) in *Shp-1* null HSCs ([Fig. 5 F](#fig5){ref-type="fig"}). Thus, our in vivo data proved that SHP-1 is critical for TGF-β signaling enforced regulation of HSC quiescence.

SHP-1 is suggested as a negative signal regulator and plays a suppressive role in myeloid immune cells ([@bib18]; [@bib24]; [@bib10]; [@bib31]; [@bib36]; [@bib38]; [@bib28]); however, its role in HSCs is less clear. Using conditional knockout and BM reconstitution assay, we demonstrated that SHP-1 is essential for HSC quiescence and long-term self-renewal maintenance. Our previous work identified that ∼20% HSCs are surrounded by MKs, which produce TGF-β and other signals such as CXCL4 for HSC quiescence maintenance ([@bib4]; [@bib42]; [@bib20]). However, the identity of this MK-adjacent HSC subpopulation and their intrinsic regulatory mechanisms are largely unknown. In this work, we found that HSCs with active SHP-1 are surrounded by MKs. Our functional data further demonstrated that SHP-1 is a critical downstream effector of TGF-β signaling in regulating HSCs. First, either *Shp-1* knockout from HSCs or *TGF-β1* knockout from MKs led to increased activation, but attenuated long-term self-renewal of HSCs. Second, SHP-1 physically interacts with ITIM receptor TβRI and is critical for activation of SMAD2, a TGF-β downstream effector. Third, SHP-1 knockout HSCs do not respond to TGF-β signaling in cell cycle regulation both in vitro and in vivo. The data clearly indicated that SHP-1 is indispensable for TGF-β mediated HSC quiescence maintenance as illustrated in [Fig. 5 G](#fig5){ref-type="fig"}. SHP-1 deficient HSCs have increased expression of Smad7, which promotes HSPC proliferation in a retroviral overexpression system ([@bib3]). However, the in vivo function of Smad7 in TGF-β--SHP-1 pathway for HSC regulation need further characterization.

The data also suggested that SHP-1 activates TβRI by overcoming the ITIM-mediated negative effect. Paired immunoglobulin-like receptor B, an ITIM receptor, is important for both normal HSC self-renewal and leukemia development potentially through interacting with SHP-2 and SHP-1 ([@bib45]). We previously showed that the LAIR1--SHP-1 pathway is essential for acute myeloid leukemia development and acute myeloid leukemia stem cell regulation, but LAIR1-deficient mice maintain normal hematopoiesis and HSC function ([@bib12]). Here, we identified that TβRI--SHP-1 regulates the maintenance of HSC quiescence. This indicated that ITIM receptors have overlapping yet distinct functions in regulating hematopoiesis and leukemogenesis. Because SHP-1 is suggested to be involved in leukemogenesis ([@bib38]; [@bib5]), further characterization is needed to understand the function of TGF-β--SHP-1 pathway in leukemogenesis. Overall, our observation provided a novel intrinsic molecular mechanism to understand how HSC quiescence is regulated by niche signals.

Materials and methods {#s07}
=====================

Animals {#s08}
-------

B6.129P2-Ptpn6tm1Rsky/J (*Shp-1*^fl/fl^), *Tgfb1*tm2.1Doe/J (*Tgfb1*^fl/fl^), and C57BL/6-Tg(*Pf4-cre*)Q3Rsko/J (*Pf4-cre*) mice were obtained from the Jackson Laboratory. *Scl-Cre*ER mice were provided by J.R. Goethert. *Scl-CreER* mice were mated with the *Shp-1*^fl/fl^ line to generate *Scl-CreER*; *Shp-1*^fl/fl^ mice. For induction of Cre-ER recombinase, mice were administered tamoxifen by oral gavage (10 mg/0.5 ml sunflower oil; Sigma-Aldrich). *Tgfb1*^fl/fl^ mice were mated with the *Pf4-cre* line to generate *Pf4-cre*; *Tgfb1*^fl/fl^ mice ([@bib33]). All experimental mice were a mix of male and female 6--8-wk-old mice. TGF-β1 inhibitor LY364947 (S2805; Selleckchem) was intraperitoneally injected at 1 mg/kg. All mouse strains used in this study had a C57BL/6J genetic background. Animals were randomly included in the experiments according to genotyping results. Animals were blindly selected. The figure legends detail the number of animals used per study. All animal experiments were performed according to protocols approved by the institutional animal care and use committee.

PCR genotyping {#s09}
--------------

Tissues were lysed in lysis buffer (Tissue PCR kit; Sigma-Aldrich) according to the manufacturer's instruction. Mice were genotyped by PCR for 3 min at 95°C (20 s at 95°C, 30 s at 60°C, and 30 s at 72°C) 30 times and 3 min at 72°C. Shp-1 genotyping PCR primers were 5′-ACCCTCCAGCTCCTCTTC-3′, 5′-TGAGGTCCCGGTGAAACC-3′, and 5′-TGTTATGCATGTGTGTATCG-3′. *Scl-CreER* genotyping PCR primers were 5′-GAACCTGAAGATGTTCGCGAT-3′ and 5′-ACCGTCAGTACGTGAGATATC-3′. *Tgfb1*^fl/fl^ genotyping PCR primers were 5′-AAGACCTGGGTTGGAAGTG-3′ and 5′-CTTCTCCGTTTCTCTGTCACCCTAT-3′. *Pf4*-*cre* genotyping PCR primers were 5′-CCAAGTCCTACTGTTTCTCACTC-3′ and 5′-TGCACAGTCAGCAGGTT-3′.

Flow cytometry {#s10}
--------------

For phenotype analysis, hematopoietic cells were harvested from BM (femur and tibia). In brief, two million BM cells were resuspended in 100 µl cold PBS with 2% FBS and were blocked with PE-Cy7 anti--mouse CD16/CD32 (93; eBioscience; 1:200). After 15 min, 2 µl biotin anti--mouse Lineage depletion cocktail (BD Biosciences) was added, and the samples were kept on ice for 30 min. Cells were spun down, resuspended in 100 µl cold PBS with 2% FBS, and stained with streptavidin PerCP-Cyc5.5 (eBioscience, 1:200), APC-eFluor 780 anti-mouse c-Kit (eBioscience, 2B8, 1:200), eFluor 450 anti-mouse CD34 (eBioscience, RAM34, 1:50), eFluor 660 anti-mouse CD127 (eBioscience, A7R34, 1:50), FITC anti--mouse Sca-1 (E13-161.7; BD Biosciences; 1:200), or PE-CF594 anti--mouse CD135 (A2F10.1; BD Biosciences; 1:100). Samples were kept on ice for 1 h after addition of antibody and then washed with 100 µl of cold PBS with 2% FBS. Cells were resuspended with 300--500 µl cold PBS with 2% FBS for flow cytometry analysis. For cell cycle analysis, the cells were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer's protocol. In brief, 150 µl Foxp3 Fixation/Permeabilization working solution was added to each well, and samples were incubated for 30 to 60 min. Cells were spun down and washed twice with Permeabilization Buffer. Cells were then resuspended in 100 µl Permeabilization Buffer with 10 µg/ml Hoechst-33342 and 0.3 µl PE anti--mouse/rat Ki-67 (SolA15; eBioscience) was added. Samples were incubated in dark at room temperature for at least 30 min. Cells were washed with 200 µl Permeabilization Buffer and resuspended in 300 to 500 µl of cold PBS with 2% FBS for flow cytometry analysis as previously described ([@bib8]; [@bib43]). For apoptosis assay, the cells were stained with PE Annexin V and 7-AAD (BD Biosciences). Cell sorting and analysis were performed using a cell sorter (FACSARIA III; BD Biosciences) or flow cytometer (Attune NxT; Thermo Fisher).

Mouse competitive reconstitution analyses {#s11}
-----------------------------------------

The indicated numbers of CD45.2 total BM cells or Lin^−^Sca-1^+^Kit^+^ Flk2^−^CD34^−^ (LSKFC) cells from *Scl-CreER^+^; Shp-1^fl/fl^* mice and *Scl-CreER^--^; Shp-1^fl/fl^* control mice treated with tamoxifen; 2 × 10^5^ BM cells from *Pf4-cre^--^; TGF-β1^f/f^* or from *Pf4-cre^+^; TGF-β1^f/f^* mice (CD45.2) were mixed with 2 × 10^5^ CD45.1 competitor BM cells, and the mixture was injected intravenously into 6--8-wk-old CD45.1 mice irradiated with a total dose of 10 Gy. To measure reconstitution, peripheral blood was collected at the indicated time points after transplantation, and CD45.1^+^ and CD45.2^+^ cells in lymphoid and myeloid compartments were measured as described before ([@bib8]; [@bib44]). CRU assay was measured by ELDA ([@bib7]).

Colony assays {#s12}
-------------

BM cells were diluted to the indicated concentration in Iscove's modified Dulbecco's medium with 2% FBS and were seeded into methylcellulose medium M3434 (StemCell Technologies) for CFU-GM, CFU-GEMM, and BFU-E colony formation assays and into M3630 (StemCell Technologies) for the CFU--Pre-B colony formation assay according to the manufacturer's protocols. ([@bib45]; [@bib12]).

Immunostaining {#s13}
--------------

Femurs or tibias were perfused before removal and fixed by 4% paraformaldehyde. Frozen sections were retrieved using 1 µg/ml proteinase K in TE buffer (100 mM Tris-HCl, pH 8.0, and 50 mM EDTA) at 37°C for 30 min. Blocking was done with Universal Blocking Reagent (HK112-5K; BioGenex). Anti--mouse pSHP-1 (ab51171; rabbit; Abcam; 1:100) and anti--mouse pSMAD2 (04-953; rabbit; Millipore; 1:100) and anti--mouse glial fibrillary acidic protein (GFAP; IR524; rabbit; Dako) were used. Secondary staining was done with donkey anti--rabbit AF680 (Invitrogen; 1:1,000) and donkey anti--rabbit AF488 (Invitrogen; 1:1,000 dilution). For HSC staining in bone sections, we used anti--mouse CD150 (TC15-12F12.2; Biolegend; 1:100), anti--mouse CD48-biotin (HM48-1; Biolegend; 1:100), FITC anti--mouse CD41 (MWReg30; Thermo Fisher; 1:100), APC anti--mouse CD41, and biotin anti--mouse Lineage (biotin anti--mouse B220, CD3, CD4, CD8, Gr1, IgM, Mac-1, and Ter119; rat; Biolegend; 1:50 dilution). Secondary staining was done with donkey anti--rat Dylight 550 (SA5-10027; Invitrogen; 1:1,000) and streptavidin-Brilliant violet 421 (Biolegend; 1:1,000). For sorted HSCs staining, cells were fixed with precooled methanol. Anti--mouse SHP-1 (ab131537; rabbit; Abcam; 1:100) and anti--mouse TβRI (sc-101574; rat; Santa Cruz; 1:100) were used. For high-resolution three-dimensional images, z-stack collected images from Nikon C2plus, or Zeiss LSM-710 confocal microscopy were analyzed with Imaris software (Bitplane) and ImageJ (National Institutes of Health).

Computational modeling of random MK and HSC localization {#s14}
--------------------------------------------------------

Images of femur frozen sections were used to produce spatial maps of Schwann's cells onto which 85 MKs or 20 HSCs were randomly placed in the marrow. After delimiting the boundaries of the marrow according to the bone-to-marrow interface, background staining was removed to accurately represent Schwann's cells, MKs, or HSCs. 85 random MKs or 20 HSCs were selected from the defined region, and the shortest Euclidean distance was calculated for each MKs to Schwann's cell, or HSC to MKs and Schwann's cell. 1,000 times simulations were performed for each model. Random and actual distance distributions were compared using the modified nonparametric two-dimensional (2D) KS test as described ([@bib4]).

TGF-β1 in vitro treatment assay {#s15}
-------------------------------

LSK cells isolated from *Shp-1^+/+^* and *Shp-1^Δ/Δ^* mice were cultured in StemSpan medium (StemCell Technologies) supplemented with 50 ng/ml rmTHPO and 50 ng/ml rmSCF and treated with or without 5 ng/ml TGF-β1. 5 d later, the cells were used in CFU assay (M3434), calculated for total cell numbers, or harvested for Western blots.

Quantitative RT-PCR (RT-qPCR) {#s16}
-----------------------------

RT-qPCR was performed as described previously ([@bib12]); RT-PCR was performed on 5 ng total RNA with specific primers and a QIAGEN One Step RT-PCR kit (210210; Qiagen) according to the manufacturer's protocol. β-actin was used as the reference gene to normalize the relative expression for quantitative RT-PCR analysis. RT-qPCR primers used in this study were as follows: *Tab1*: forward (5′-ACAGCAAGCTCTACGTTGCC-3′) and reverse (5′-GTAACCTGTAACCCATCCACTG-3′); *Smad7*: forward (5′-GCATTCCTCGGAAGTCAAGAG-3′) and reverse (5′-CCAGGGGCCAGATAATTCGT-3′); *Msi2*: forward (5′-ACCTCACCAGATAGCCTTAGAG-3′) and reverse (5′-AGCGTTTCGTTGTGGGATCTC-3′); *P57^KIP2^*: forward (5′-GCAGGACGAGAATCAAGAGCA-3′) and reverse (5′-GCTTGGCGAAGAAGTCGTT-3′)'; β-actin: forward (5′-GCTCTTTTCCAGCCTTCCTT-3′) and reverse (5′-CTTCTGCATCCTGTCAGCAA-3′); and β-actin: forward (5′-GCTCTTTTCCAGCCTTCCTT-3′) and reverse (5′-CTTCTGCATCCTGTCAGCAA-3′).

Western blotting {#s17}
----------------

Cell lysates (100-µg samples) were prepared using Transmembrane Protein Extraction Reagent (TmPER-200; FIVEphoton Biochemicals) or in RIPA buffer. Proteins were separated by electrophoresis on 4--15% SDS-polyacrylamide gels, and the proteins were electroblotted onto a nitrocellulose membrane. The membrane was probed with the indicated primary antibodies for 1 h at room temperature or overnight at 4°C and then incubated with secondary antibody, which was detected by exposure to x-ray film, or by digital imaging with a charge-coupled device camera system (Odyssey Fc). The antibodies used included anti--mouse SHP-1 (ab2020; Abcam; 1:2,000 dilution), anti--mouse pSMAD2 (04-953; Millipore; 1:1,000 dilution), anti--mouse TβRI (sc-9048; Santa Cruz; 1:500 dilution), anti-FLAG (SIGI-25; Sigma-Aldrich; 1: 5,000), anti-His (Santa Cruz; 1:5,000), and anti--mouse actin (1A4; Sigma-Aldrich; 1:10,000 dilution), anti--mouse TGF-β1(ab92486; Abcam; 1:500 dilution). The images shown are representative of images from at least three experiments.

ELISAs {#s18}
------

TGF-β1 was measured by Quantikine ELISA kit (R&D Systems) following the manufacturer's instruction.

Statistical analyses {#s19}
--------------------

Data are expressed as means ± SEM. For all experiments except determination of survival, data were analyzed by Student's *t* test, and differences were considered statistically significant if P \< 0.05. The survival of the two groups were analyzed using a log-rank test, and differences were considered statistically significant if P \< 0.05. Comparisons of probability distributions between two samples were done using two-sample KS test, and 2D distance distributions that were derived from the actual measurements and random simulations were compared using a nonparametric 2D KS test with two samples. Differences were considered statistically significant if P \< 0.05. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.

Online supplemental material {#s20}
----------------------------

Fig. S1 shows loss of *Shp-1* results in HSC activation in early time point. Fig. S2 shows the loss of *Shp-1* in MK niche does not compromise HSC quiescence. Fig. S3 shows the spatial relationship of pSHP-1^+^ HSCs with MKs in BM.
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